Dark

Check out our Level2View

THRX
Theseus Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive

Feb 13, 2024

4.06USD0.000%(0.00)3,123,140

Pre-market

0.00USD-100.000%(-4.06)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 14, 2022

11:52AM EST Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Profit Tops Views Benzinga

Jan 10, 2022

07:26AM EST Theseus Pharmaceuticals Announces First Patient Treated With THE-630 In Phase 1/2 Study In Patients with Advanced Gastrointestinal Stromal Tumors Benzinga

Dec 17, 2021

08:00AM EST Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in PR Newswire

Nov 15, 2021

10:56AM EST Theseus Pharmaceuticals Q3 EPS $(5.16) Benzinga

07:14AM EST Theseus Pharmaceuticals Q3 Net Loss Widens To $7.4 Mln From $1.4 Mln Last Year RTTNews

07:01AM EST Theseus Pharmaceuticals Announces Business and Program Highlights and Reports PR Newswire

Nov 10, 2021

07:02AM EST Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare PR Newswire

Nov 1, 2021

11:52AM EDT UPDATE: SVB Leerink On Theseus Outperform Initiation: Firm Highlights Co.'s Lead Asset THE-630, Which 'Covers All Known Major Classes Of KIT Activating & Resistance Mutations In GIST'; Notes EGFR Inhibitor Program As Additional Key Value Driver Benzinga

08:25AM EDT 08:24 Monday, November 1, 2021Wedbush (RTTNews) - Wedbush Starts THERAVANCE, INC. (THRX) At Outperform With $24 Price Target RTTNews

08:11AM EDT Cantor Fitzgerald Initiates Coverage On Theseus Pharmaceuticals with Overweight Rating, Announces Price Target of $25 Benzinga

07:35AM EDT Wedbush Initiates Coverage On Theseus Pharmaceuticals with Outperform Rating, Announces Price Target of $24 Benzinga

07:07AM EDT Theseus Pharmaceuticals Announces FDA Clearance Of Investigational New Drug Application For THE-630, A Pan-Variant KIT Inhibitor In Development For The Treatment Of Gastrointestinal Stromal Tumors Benzinga

06:37AM EDT SVB Leerink Initiates Coverage On Theseus Pharmaceuticals with Outperform Rating, Announces Price Target of $28 Benzinga

05:52AM EDT Jefferies Initiates Coverage On Theseus Pharmaceuticals with Buy Rating, Announces Price Target of $23 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 7, 2021

11:34AM EDT Theseus Pharmaceuticals Shares Open For Trade At $20.80; IPO Priced At $16/Share Benzinga

11:19AM EDT Theseus Pharmaceuticals Indicating $21/Share Benzinga

11:17AM EDT Theseus Pharmaceuticals Shares Indicating $25 On 220K Shares Benzinga

11:10AM EDT Theseus Pharmaceuticals Shares Indicating $32; IPO Priced At $16/Share Benzinga

09:24AM EDT Theseus Pharmaceuticals Shares Will Open For Quote At 11 a.m. EDT, Expected To Open For Trade After 11:10 a.m. EDT; IPO Priced At $16/Share Benzinga

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

10:37PM EDT Theseus Pharma Prices IPO Of 10.00 Mln Shares At $16.00/shr RTTNews

10:21PM EDT Theseus Pharmaceuticals Announces Pricing of Initial Public Offering PR Newswire

Share